Timing is everything, especially when it comes to investing. As Chromadex Corp continues to capture attention on the NASDAQ, investors are buzzing about its potential. With a strong buy consensus from analysts and a target price estimated at 5.17, there's a palpable sense of anticipation surrounding this consumer defensive stock. However, it's crucial to weigh these optimistic projections against the company's recent performance, which includes a reported loss. This moment presents a unique opportunity to reevaluate your investment strategy, considering both the potential upside and the inherent risks. As we navigate this unique economic climate, Chromadex Corp might surprise investors in the coming week. Recent price movements hint at a potential rebound in December. Currently, Chromadex Corp is trading at $6.99. The company's historical hype elasticity stands at 0.27, compared to an industry average of 0.19. It's expected that the stock will rise following the next press release, potentially reaching $6.35. However, the stock's volatility, driven by headline impacts, exceeds 100%, making social media predictions less reliable. The anticipated price increase with the next news is around 3.93%, while the daily expected return is 1.7%. With a 90-day investment horizon, the next announcement is expected in about nine days.
Chromadex Corp technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Chromadex Corp
financial leverage refers to using borrowed capital as a funding source to finance Chromadex Corp ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Chromadex Corp financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Chromadex Corp's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Chromadex Corp's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Chromadex Corp's total debt and its cash.
The company reported the previous year's revenue of 83.57
M. Net Loss for the year was (4.94
M) with profit before overhead, payroll, taxes, and interest of 42.8
M.
| 2021 | 2022 | 2023 | 2024 (projected) |
Short Long Term Debt Total | 4.7M | 4.3M | 3.3M | 1.7M | Total Assets | 57.8M | 54.1M | 55.0M | 28.4M |
Current Deferred Revenue Breakdown
Chromadex Corp's Current Deferred Revenue is decreasing over the years with stable fluctuation. Overall, Current Deferred Revenue is expected to go to about 263.8
K this year. Current Deferred Revenue usually refers to revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. At present, Chromadex Corp's Current Deferred Revenue is projected to decrease significantly based on the last few years of reporting.
| 2017 | 314,335 |
| 2018 | 275,000 |
| 2019 | 169,000 |
| 2020 | 278,000 |
| 2021 | 161,000 |
| 2022 | 157,000 |
| 2023 | 195,000 |
| 2024 | 263,770 |
As the saying goes, "Timing is everything in investing," and for Chromadex Corp, now might be the moment to reevaluate your strategy. With a market capitalization of $466.7 million and a promising target price of $7.20, Chromadex presents intriguing prospects for investors. Despite the modest profit margin of 0.02%, the company's solid working capital of $28.91 million provides a buffer to navigate market uncertainties. The insider ownership of 35.39% suggests confidence from those closest to the company, potentially aligning their interests with shareholders. As you consider your next move, weigh these factors carefully to determine if Chromadex aligns with your investment goals.
Over 3 percent surge for Chromadex Corp. What does it mean for shareholders?
Chromadex Corp's recent stock increase of over 3% is encouraging for shareholders, especially with the company's information ratio rising above 0.16. This figure, which evaluates risk-adjusted returns, indicates that Chromadex is effectively managing its volatility while still delivering returns. For investors, this suggests a potentially more stable and rewarding investment, as the company seems to be balancing risk and performance well. The improved information ratio might also signal enhanced operational efficiencies or successful strategic initiatives, offering a positive outlook for shareholders.
However, Chromadex Corp is experiencing above-average volatility. Understanding these market trends can help investors make informed decisions.
High volatility, especially in bear markets, can significantly affect stock prices, prompting investors to adjust their portfolios as prices fluctuate.Considering the current dynamics surrounding Chromadex Corp, investors are faced with a decision that hinges on both potential risks and opportunities. The stock's valuation market value sits at
6.99, which suggests room for growth when juxtaposed with the analyst's highest estimated target price of
5.74. This discrepancy might indicate an undervaluation or a market mispricing, presenting a possible upside. Furthermore, the analyst overall consensus leans towards a strong buy, supported by three strong buy recommendations. However, it's crucial to weigh these optimistic signals against the inherent volatility and specific challenges the company may face. Ultimately, whether to hold or divest depends on your risk tolerance and investment horizon..
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Chromadex Corp. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com